Treatment with formoterol/budesonide in patients with asthma

Treatment with formoterol/budesonide in patients with asthma - Treatment of formoterol/budesonide for asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005185

Enrollment

130

Registered

2011-03-03

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

Switch from salmeterol/fluticasone one inhalation twice daily to formoterol/budesonide two inhalation twice daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Salmeterol/budesonide 50/250ug one inhalation twice daily at constant dose for >2 months Ability and willingness to provide informed consent

Exclusion criteria

Exclusion criteria: History of hypersensitivity to budesonide History or presence of lung, cardiac, renal and liver desease Use of systemic corticosteroids

Design outcomes

Primary

Measure	Time frame
FEV1 at week 0 and week 12	—

Secondary

Measure	Time frame
V50 at week 0 and week 12 V25 at week 0 and week 12 FVC at week 0 and week 12 Exhaled NO at week 0 and week 12 Adverse events at week 0 and week 12 Mean rate of all exacerbations at week 0 and week 12	—

Countries

Japan

Contacts

Public ContactTaisuke Akamatsu

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026